Verdona G, Garaventa A, Coviello D A, Cornaglia-Ferraris P, Tonini G P
Boll Ist Sieroter Milan. 1986;65(4):304-8.
N-myc oncogene is amplified in several human neuroblastoma cell lines and fresh neoplastic tissues; amplification would be highly correlated with advanced stages of neoplasia and associated with poor outcome of the disease. According to these data, N-myc amplification should be a new prognostic marker in addition to classical clinical and laboratory findings commonly monitored in neuroblastoma; some of them are levels of urinary Vanillylmandelic Acid (VMA) and Homovanillic Acid (HVA), serum Lactic Dehydrogenase (LDH) and serum Ferritin (sFe). We studied 4 patients in stage III and IV; N-myc amplification was detected in 2 cases in stage IV in primary tumor cells and in one case this finding was associated with high levels of serum Ferritin and LDH, while no correlation between other laboratory parameters and N-myc amplification has been found. We propose that N-myc amplification has to be evaluated with other prognostic factors to obtain useful information about the disease and the survival of the patient.
N - myc癌基因在几种人类神经母细胞瘤细胞系和新鲜肿瘤组织中呈扩增状态；这种扩增与肿瘤的晚期高度相关，并与疾病的不良预后相关。根据这些数据，除了神经母细胞瘤中通常监测的经典临床和实验室检查结果外，N - myc扩增应成为一种新的预后标志物；其中一些经典检查结果包括尿香草扁桃酸（VMA）和高香草酸（HVA）水平、血清乳酸脱氢酶（LDH）和血清铁蛋白（sFe）。我们研究了4例III期和IV期患者；在IV期的2例原发性肿瘤细胞中检测到N - myc扩增，在1例中该发现与血清铁蛋白和LDH的高水平相关，而未发现其他实验室参数与N - myc扩增之间存在相关性。我们建议，必须将N - myc扩增与其他预后因素一起评估，以获得有关疾病和患者生存的有用信息。
